Singapore markets close in 5 hours 24 minutes

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6955-0.0595 (-7.88%)
At close: 03:59PM EDT
0.7218 +0.03 (+3.78%)
After hours: 06:50PM EDT

NLS Pharmaceutics AG

The Circle 6
Zurich 8058
41 44 512 21 50

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Alexander Zwyer M.B.A.Pres, CEO & Director1.07MN/A1969
Dr. George Apostol M.D.Chief Medical Officer and Global Head of R&D154kN/A1973
Dr. Eric Konofal M.D., Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1967
Ms. Elena Thyen-PighinChief Financial OfficerN/AN/AN/A
Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D.Gen. CounselN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Corporate governance

NLS Pharmaceutics AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.